1
Clinical Trials associated with Allogeneic Hematopoietic Stem Cell(Northwestern University)Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease
Allogeneic transplantation has been a high-risk procedure, although non-myeloablative conditioning regimens (mini-transplantation) minimizes regimen related toxicity. The investigators, therefore, propose a phase I study of matched sibling allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning. In addition, graft versus host disease (GVHD) will be virtually eliminated by CAMPATH that removes donor T cells from the graft.
The goal is to assess the toxicity/efficacy (phase I) of allogeneic non-myeloablative hematopoietic stem cell transplantation for high-risk Crohn's disease. In simplistic terms, this protocol is designed to ablate an aberrant immune system and then, similar to the use of marrow transplants for immunodeficient patients, reconstitute a new immune system with lymphocyte depleted marrow.
100 Clinical Results associated with Allogeneic Hematopoietic Stem Cell(Northwestern University)
100 Translational Medicine associated with Allogeneic Hematopoietic Stem Cell(Northwestern University)
100 Patents (Medical) associated with Allogeneic Hematopoietic Stem Cell(Northwestern University)
100 Deals associated with Allogeneic Hematopoietic Stem Cell(Northwestern University)